Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258930 | 0.85 | ALDH1A1 (0.38) | KDM4EKMT2ACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL17997419 | 0.85 | CYP1A2 (0.46) | KDM4EKMT2ACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL12869547 | 0.83 | ALDH1A1 (0.37) | CYP1A2CYP2D6ALDH1A1FFAR3 | |
| SCHEMBL15461461 | 0.83 | ALDH1A1 (0.37) | CYP1A2CYP2D6ALDH1A1FFAR3 | |
| SCHEMBL8741458 | 0.82 | KDM4E (0.44) | KDM4EKMT2ACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL5240027 | 0.82 | KDM4E (0.63) | KDM4EKMT2ACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL12869545 | 0.81 | ALDH1A1 (0.36) | CYP1A2CYP2D6ALDH1A1FFAR3 | |
| SCHEMBL19736453 | 0.79 | KDM4E (0.42) | KDM4EKMT2ACYP1A2CHRM5CHRM3 | |
| SCHEMBL16750982 | 0.79 | KDM4E (0.69) | KDM4EKMT2ACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL6008945 | 0.77 | KMT2A (0.56) | KDM4EKMT2ACYP1A2ALDH1A1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183912-A1 | ANTIVIRAL PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| EP-1558615-B1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183912-A1 | ANTIVIRAL PRODRUGS OF TENOFOVIR | PNP, TYMP, HPRT1 | KDM4E 2938/4885KMT2A 4200/4885CYP1A2 800/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | KDM4E 614/4885KMT2A 1237/4885CYP1A2 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.